Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 17,841 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Patient Control Clear all

Conditions: Osteoporosis
Interventions: Mailed education, Telephone coaching program for patients, Medication adherence alert program for doctors; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 2,087 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatic Impairment
Interventions: Iloperidone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Anaheim, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: Diabetes Mellitus
Interventions: Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT); Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 25 Years to 85 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gender Dysphoria, Mastectomy, Hypertrophic Scar
Interventions: Brijjit® BP100-6 and BP-75, Control: Standard of care and normal wound dressing; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 19 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Migraine
Interventions: Greater occipital nerve block, Bupivacaine; Procedure · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
Interventions: Hepatitis C testing; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cold Agglutinin Disease
Interventions: sutimlimab (BIVV009), placebo; Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Georgetown, District of Columbia + 10 more

Conditions: Bipolar I Disorder
Interventions: Intramuscular (IM) Depot Aripiprazole, Intramuscular (IM) Depot Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 39 more

Conditions: Vaccine Hesitancy
Interventions: EHR alert, Motivational Interviewing, Warm hand off to nurse; Other · Behavioral
Lead sponsor: Boston College; Other
Eligibility: 18 Years and older
Enrollment: 3,698 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
Interventions: anifrolumab, Placebo; Drug · Other
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Partial Onset Seizures
Interventions: Investigational new drug, company code: BGG492, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 10 more

Conditions: Osteoarthritis, Knee, Hypertension
Interventions: STAR Intervention, Attention-Control; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Asthma
Interventions: Imatinib mesylate, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 4 more

Conditions: Opioid-use Disorder, Addiction, Depression, Post-traumatic Stress Disorder
Interventions: Collaborative Care; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Santa Monica, California • Albuquerque, New Mexico + 5 more

Conditions: Prostate Cancer
Interventions: Amount of Pneumoperitoneum Pressure applied during RARP; Procedure
Lead sponsor: Metro Health, Michigan; Other
Eligibility: 40 Years and older · Male only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Wyoming, Michigan

Conditions: Alopecia Areata
Interventions: SHR0302; Drug
Lead sponsor: Reistone Biopharma Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Northridge, California • Brandon, Florida • Indianapolis, Indiana + 4 more

Conditions: Asthma
Interventions: SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 18
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more

Conditions: BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Interventions: Furosemide; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Ocrelizumab; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 732 participants
Timeline: 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Bipolar Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 28
States / cities: Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more

Conditions: Rheumatoid Arthritis
Interventions: AIN457, Placebo, Abatacept; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 44
States / cities: Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more

Conditions: Breast Cancer
Interventions: Fulvestrant, BKM120, BKM120 matching placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 61
States / cities: Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more

Conditions: Pregnancy Related, Elective Induction
Interventions: Shared decision-making with a Decision-aid, routine shared decision-making; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Parkinson Disease, Parkinson
Interventions: Serious games; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Newark, New Jersey

Search by objective public record fields.

Evaluating Ways to Improve Medication Use Among People With Osteoporosis

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Interprofessional Training to Improve Diabetes Care: The ReSPECT Trial

Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy

Greater Occipital Nerve Block With Bupivacaine for Acute Migraine

Association Between Hepatitis C Infection and Renal Cell Carcinoma

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

Motivational Interviewing for Vaccine Uptake in Latinx Adults

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

Staying Active With Arthritis: RCT of Physical Activity for Older Adults With Osteoarthritis and Hypertension

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Collaboration Leading to Addiction Treatment and Recovery From Other Stresses

The Impact of Low Pressure Pneumo in RARP

A Phase II Study in Patients With Alopecia Areata

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Decision Aid to Assist Low-Risk Nulliparous Women Considering Induction of Labor At 39 Weeks

Serious Games for Parkinson's Disease